LTR Pharma (CHIA:LTP) - Stock Price, News & Analysis

LTP Stock Overview

A biopharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia, and the United States.

About the company

LTP fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Risk Analysis

Highly volatile share price over the past 3 months

Has not reported any financial data

Does not have a meaningful market cap (A$125M)

LTR Pharma Limited Competitors

Argenica Therapeutics

ASX:AGN

AU$102.7m

Recce Pharmaceuticals

ASX:RCE

AU$96.9m

Vita Life Sciences

ASX:VLS

AU$123.9m

Arovella Therapeutics

ASX:ALA

AU$157.6m

Price History & Performance

Summary of all time highs, changes and price drops for LTR Pharma
Historical stock prices
Current Share Price	AU$0.91
52 Week High	AU$1.05
52 Week Low	AU$0.24
Beta	0
11 Month Change	42.19%
3 Month Change	203.33%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	193.55%

Recent updates

Shareholder Returns

	LTP	AU Pharmaceuticals	AU Market
7D	18.2%	-1.0%	0.9%
1Y	n/a	61.8%	9.6%

Return vs Industry: Insufficient data to determine how LTP performed against the Australian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how LTP performed against the Australian Market.

Price Volatility

Is LTP's price volatile compared to industry and market?
LTP volatility
LTP Average Weekly Movement	19.2%
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	8.4%
10% most volatile stocks in AU Market	16.9%
10% least volatile stocks in AU Market	3.2%

Stable Share Price: LTP's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine LTP's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2020	n/a	n/a	www.ltrpharma.com

LTR Pharma Limited, a biopharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia, and the United States. Its lead product candidate is SPONTAN, an intranasal delivery technology for safe and effective oral PDE5 inhibitor and vardenafil HCL. LTR Pharma Limited was incorporated in 2020 and is based in Brisbane, Australia.

LTR Pharma Limited Fundamentals Summary

How do LTR Pharma's earnings and revenue compare to its market cap?
LTP fundamental statistics
Market cap	AU$125.48m
Earnings (TTM)	AU$0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is LTP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LTP income statement (TTM)
Revenue	AU$0
Cost of Revenue	AU$0
Gross Profit	AU$0
Other Expenses	AU$0
Earnings	AU$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did LTP perform over the long term?

See historical performance and comparison

LTR Pharma CHIA:LTP Stock Report